Sugi Predict

Sugi Predict / Compounds / SCHEMBL28487

SCHEMBL28487

SCHEMBL28487

Cn1ccc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 13/20 0.44
▸ LIPG Q9Y5X9 13/20 0.44
▸ FFAR1 O14842 1/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA6 P23280 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38
▸ F11 P03951 1/20 0.37
▸ MAPK1 P28482 1/20 0.34
▸ ESR2 Q92731 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25176691 0.82 LPL (0.46) LPLLIPGFFAR1CA1CA2
SCHEMBL21201773 0.78 LPL (0.43) LPLLIPGFFAR1CA1CA2
SCHEMBL16434592 0.77 LPL (0.42) LPLLIPGFFAR1CA1CA2
SCHEMBL20211301 0.77 CA1 (0.47) LPLLIPGCA1CA2CA9
SCHEMBL25171193 0.76 LPL (0.46) LPLLIPGFFAR1CA1CA2
SCHEMBL28812112 0.74 LPL (0.40) LPLLIPGFFAR1CA1CA2
SCHEMBL12502599 0.73 LIPG (0.42) LPLLIPGFFAR1CA1CA2
SCHEMBL28739 0.72 LPL (0.38) LPLLIPGFFAR1CA1CA2
SCHEMBL24519347 0.72 LPL (0.39) LPLLIPGFFAR1CA1CA2
SCHEMBL21729587 0.72 LPL (0.38) LPLLIPGFFAR1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026086794-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF THE CHINESE UNIVERSITY OF HONG KONG (CN) 2026-04-30 — — WO disclosed
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LTD (CN) 2025-11-27 — — US disclosed
US-12435062-B2 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2025-10-07 — — US disclosed
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 — — US disclosed
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-02-20 — — US disclosed
WO-2025036241-A1 COMPOUNDS AND METHODS FOR MODULATING RNA SPLICING RIBOPEUTIC INC. (CN) 2025-02-20 — — WO disclosed
US-20240308998-A1 PYRROLOPYRIDONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Tay Therapeutics Limited (GB) 2024-09-19 — — US disclosed
EP-3997096-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2024-08-28 — — EP disclosed
US-20240199641-A1 QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 UNIV VANDERBILT (US) 2024-06-20 — — US disclosed
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 — — CN disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 — — US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 — — US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 — — US disclosed
EP-2004615-A2 QUINAZOLINES FOR PDK1 INHIBITION Novartis AG (CH) 2008-12-24 — — EP disclosed
WO-2007117607-A9 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTIC (US) 2008-03-06 — — WO disclosed
WO-2007117607-A9 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTIC (US) 2008-03-06 — — WO disclosed
WO-2007117607-A2 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS AG (CH) 2007-10-18 — — WO disclosed
WO-2007117607-A2 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS AG (CH) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240308998-A1 PYRROLOPYRIDONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER TP53, PYCR1, TPMT LPL 4063/4885LIPG 4070/4885FFAR1 4196/4885
US-20240199641-A1 QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 GRM2, GRIN2A, GRIN2C LPL 4373/4885LIPG 4789/4885FFAR1 238/4885
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 LPL 1442/4885LIPG 1293/4885FFAR1 1395/4885
US-12435062-B2 Amide compounds and uses thereof ASNS, ASS1, NAT1 LPL 2681/4885LIPG 2442/4885FFAR1 2210/4885
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, NAT1, AADAC LPL 2213/4885LIPG 1915/4885FFAR1 2945/4885
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 LPL 1309/4885LIPG 1304/4885FFAR1 3527/4885
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 LPL 1381/4885LIPG 1144/4885FFAR1 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.